Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2005-10-21
2010-11-02
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S572000, C514S573000, C562S405000, C562S492000, C562S503000, C562S505000, C562S508000
Reexamination Certificate
active
07825160
ABSTRACT:
The present invention relates to compounds having the general formula (I) with the definitions of A, X, R1-R6given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment of Alzheimer's disease and their use for the modulation of γ-secretase activity.
REFERENCES:
patent: 6869975 (2005-03-01), Abe et al.
patent: 2004/073705 (2004-09-01), None
De Felice et. al., Cellular and Molecular Neurobiology, 2002, Plenum Publishing Corp., vol. 22, pp. 545-563.
Haruhiko Akiyama et al., “Inflammation and Alzheimer's Disease”, Neurobiology of Aging 21 21 (2000) pp. 383-421, Open peer commentary.
Patrick L. NcGeer et al., “Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies”, Neurology 1996;47, pp. 425-432.
J. Rogers et al., “Clinical trial of indomethacin in Alzheimer's disease”, Neurology Aug. 1993; 43, pp. 1609-1611.
J.C. Anthony et al., “Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists” The Cache County Study, Neurology 2000; 54 pp. 2066-2071.
Walter F. Stewart et al., “Risk of Alzheimer's disease and duration of NSAID use”, Neurology 1997; 48, pp. 626-632.
T. Veld et al., “NSAIDs and Incident Alzheimer's Disease. The Rotterdam Study”, Neurobiology of Aging, vol. 19, No. 6, pp. 607-611, 1998.
Sascha Weggen et al., “A subset of NSAIDs lower amyloidogeic AB42 independently of cyclooxygenase activity”, Nature, vol. 414, Nov. 8, 2001, pp. 212-216.
T. Morihara et al., Rapid Communication “Selective inhibition of AB42 production of NSAID R-enantiomers”, 2002 International Society for Neurochemistry, Journal of Neurochemistry, 83, pp. 1009-1012.
Jason L. Eriksen et al., “NSAIDs and enantiomers of flurbiprofen target y-secretase and lower AB42 in vivo”, The Journal of Clinical Investigation, Aug. 2003, vol. 112, No. 3, pp. 440-449.
Yoshihiko Yoshimoto et al., “Nonsteroidal Antiinflammatory Agents. 1. 5-Alkoxy-3-biphenylylacetic Acids and Related Compounds as New Potential Antiinflammatory Agents”, Journal of Medicinal Chemistry, 1977, vol. 20, No. 5, pp. 709-714.
Boussard Cyrille
Burckhardt Svenja
Cansfield Andrew
Harrison Richard John
Hernandez-Perni Remedios
Cellzome Limited
J.A. Lindeman & Co., PLLC
Padmanabhan Sreeni
Pihonak Sarah
LandOfFree
(Biphenyl) carboxylic acids and derivatives thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (Biphenyl) carboxylic acids and derivatives thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (Biphenyl) carboxylic acids and derivatives thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4210937